Cancer survival rates have improved dramatically over the past few decades thanks to ongoing advances in therapeutics. As research continues to push the boundaries of medicine, two innovative technologies stand out in the fight against cancer: Antibody-Drug Conjugates (ADCs) and PROteolysis TArgeting Chimeras (PROTACs). These cutting-edge approaches are refining how we treat cancer and opening…

For all the buzz around the Inflation Reduction Act (IRA), opinions on its impact are sharply divided – especially in the life sciences sector. Critics argue that the IRA’s drug pricing provisions, particularly Medicare price negotiation, will stifle innovation by reducing incentives for pharmaceutical companies to invest in research and development.  But these concerns don’t…

Nurse Practitioners (NPs) and Physician Assistants (PAs) are no longer just “support” staff for physicians. These clinicians are now taking on much bigger roles in patient care, including the ability to prescribe medications without physician oversight.  The COVID-19 pandemic accelerated the already growing trend of expanding NPs’ and PAs’ scope of practice. Now, five years…

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Learn more about what PurpleLab can do for Clinical Trials Life Sciences Download

The digital advertising landscape is shifting rapidly, and for healthcare and pharmaceutical marketers, the stakes are higher than ever. With evolving privacy regulations, increasing scrutiny on data practices and the challenge of balancing precision targeting with consumer protection, advertisers must rethink their strategies to stay effective and compliant. To tackle these pressing issues, PurpleLab recently…

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

PurpleLab®, a leading health tech company specializing in real-world data and medical claims insights, and Payerset, the industry leader in enterprise price transparency data, announced today a strategic partnership to launch a trusted price intelligence solution suite, setting a new standard in healthcare intelligence.  This collaboration empowers healthcare organizations with unparalleled accuracy and actionable insights,…